Socioeconomic and ethnic differences in use of lipid-lowering drugs after deregulation of simvastatin in the UK: The Whitehall II prospective cohort study

Atherosclerosis

Volumn 215, Issue 1, 2011, Pages 223-228

  Forde, Ian ^a   Chandola, Tarani ^b   Raine, Rosalind ^a   Marmot, Michael G ^a   Kivimaki, Mika ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Cardiovascular risk; Ethnicity; Inequalities; Pharmacoepidemiology; Socioeconomic position; Statin

Indexed keywords

ANTILIPEMIC AGENT; SIMVASTATIN;

ADULT; AGED; ARTICLE; ASIAN; CARDIOVASCULAR RISK; COHORT ANALYSIS; CORONARY RISK; DRUG USE; ETHNIC DIFFERENCE; FEMALE; HIGH RISK POPULATION; HUMAN; ISCHEMIC HEART DISEASE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OUTCOME VARIABLE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; SOCIOECONOMICS; UNITED KINGDOM;

AGED; COHORT STUDIES; CORONARY DISEASE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GREAT BRITAIN; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; INDIA; MALE; MIDDLE AGED; NONPRESCRIPTION DRUGS; PROSPECTIVE STUDIES; RISK; SIMVASTATIN; SOCIOECONOMIC FACTORS;

EID: 79952102135     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.12.012     Document Type: Article

References (25)

1. Department of Health Choosing health: making healthy choices easier 2004, Department of Health, England.
2. Johnson & Johnson MSD Consumer Pharmaceuticals Zocor heart-pro 10mg tablets, summary of product characteristics 2004, Johnson & Johnson MSD Consumer Pharmaceuticals, UK.
3. Department of Health. Press release, England, ; 2004. http://www.dh.gov.uk/en/Publicationsandstatistics/Pressreleases/DH_4082004.
4. OTC statins: a bad decision for public health. Lancet 2004, 363(9422):1659.
5. Sanderson B.K., Raczynski J.M., Cornell C.E., et al. Ethnic disparities in patient recall of physician recommendations of diagnostic and treatment procedures for coronary disease. Am J Epidemiol 1998, 148(8):741-749.
6. Ward P.R., Noyce P.R., St Leger A.S. Are GP practice prescribing rates for coronary heart disease drugs equitable? A cross sectional analysis in four primary care trusts in England. J Epidemiol Community Health 2004, 58(2):89-96.
7. Ramsay S.E., Morris R.W., Papacosta O., et al. Secondary prevention of coronary heart disease in older British men: extent of inequalities before and after implementation of the National Service Framework. J Public Health 2005, 27(4):338-343.
8. Murphy N.F., Simpson C.R., MacIntyre K., et al. Prevalence, incidence, primary care burden and medical treatment of angina in Scotland: age, sex and socioeconomic disparities: a population-based study. Heart 2006, 92(8):1047-1054.
9. Marmot M.G., Brunner E.J. Cohort profile: the Whitehall II Study. Int J Epidemiol 2005, 34:251-256.
10. Anderson K.M., Wilson P.W., Odell P.M., et al. An updated coronary risk profile. A statement for health professionals. Circulation 1991, 83(1):356-362.
11. British Heart Foundation JBS guidelines on the prevention of cardiovascular disease in clinical practice: risk assessment 2006, British Heart Foundation.
12. Ferrie J.E., Kivimaki M., Singh-Manoux A., et al. Non-response to baseline, non-response to follow-up and mortality in the Whitehall II cohort. Int J Epidemiol 2009.
13. Capewell S., Unal B., Critchley J.A., et al. Over 20,000 avoidable coronary deaths in England and Wales in 2000: the failure to give effective treatments to many eligible patients. Heart 2006, 92(4):521-523.
14. DeWilde S., Carey I.M., Richards N., et al. Trends in secondary prevention of ischaemic heart disease in the UK 1994 2005: use of individual and combination treatment. Heart 2008, 94(1):83-88.
15. Reid F.D., Cook D.G., Whincup P.H. Use of statins in the secondary prevention of coronary heart disease: is treatment equitable?. Heart 2002, 88(1):15-19.
16. Ashworth M., Lloyd D., Smith R.S., et al. Social deprivation and statin prescribing: a cross-sectional analysis using data from the new UK general practitioner 'Quality and Outcomes Framework'. J Public Health (Oxf) 2007, 29(1):40-47.
17. Goldman D.P., Smith J.P. Can patient self-management help explain the SES health gradient?. Proc Natl Acad Sci 2002, 99(16):10929-10934.
18. Schouten B.C., Meeuwesen L. Cultural differences in medical communication: a review of the literature. Patient Educ Couns 2006, 64(1-3):21-34.
19. Willems S., De Maesschalck S., Deveugele M., et al. Socio-economic status of the patient and doctor-patient communication: does it make a difference?. Patient Educ Couns 2005, 56(2):139-146.
20. Wardle J., Steptoe A. Socioeconomic differences in attitudes and beliefs about healthy lifestyles. J Epidemiol Community Health 2003, 57(6):440-443.
21. Lindbladh E., Hampus Lyttkens C. Polarization in the reaction to health-risk information: a question of social position?. Risk Anal 2003, 23(4):841-855.
22. Hanlon J.T., Schmader K.E., Ruby C.M., et al. Suboptimal prescribing in older inpatients and outpatients. J Am Geriatr Soc 2001, 49(2):200-209.
23. Kaplan G.A., Keil J.E. Socioeconomic factors and cardiovascular disease: a review of the literature. Circulation 1993, 88(4 Pt 1):1973-1998.
24. Balarajan R. Ethnicity and variations in mortality from coronary heart disease. Health Trends 1996, 28:45-51.
25. Grover S.A., Lowensteyn I., Joseph L., et al. Patient knowledge of coronary risk profile improves the effectiveness of dyslipidemia therapy: the CHECK-UP study: a randomized controlled trial. Arch Intern Med 2007, 167(21):2296-2303.